A Nationwide, Cohort study to evaluate the Risks associated with the treatment of Rituximab, Fingolimod and Natalizumab in Swedish patients with Multiple Sclerosis

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 15 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fingolimod (Primary) ; Natalizumab (Primary) ; Rituximab (Primary) ; Glatiramer acetate; Interferon beta
Indications Multiple sclerosis
Focus Adverse reactions

07 Oct 2019 Results examining the risk of serious infections associated with disease-modifying treatments for multiple sclerosis published in the JAMA Neurology
30 Oct 2018 New trial record
12 Oct 2018 Results assessing the risk of infections in multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com